Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-07-11
1998-03-10
Jordan, Kimberly
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514456, A61K 3140, A61K 3135
Patent
active
057262020
ABSTRACT:
The present invention provides novel uses of compounds of general formula I ##STR1## wherein R.sup.1, R.sup.4 and R.sup.5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino) (lower alkoxy); and R.sup.2 and R.sup.3 are individually hydrogen or lower alkyl, or as a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of benign prostatic hypertrophy
REFERENCES:
patent: 4310523 (1982-01-01), Neumann
Dhar, J.D. et al., Andrologia, vol. 15, No. 5, pp. 463-467, (1983).
Christensen Niels Dyhr
Guldhammer Birgitte Hjort
Korsgaard Niels
Shalmi Michael
Agris Cheryl H.
Jordan Kimberly
Novo Nordisk A S
Zelson Steve T.
LandOfFree
Benign prostatic hypertrophy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benign prostatic hypertrophy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benign prostatic hypertrophy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-139975